Early results from a trial of active surveillance for low-risk ductal carcinoma in situ are 'reassuring'

by European Organisation for Research and Treatment of CancerCredit: Unsplash/CC0 Public DomainResearchers leading a trial of active surveillance for ductal carcinoma in situ (DCIS) have described ear

Updated on: May 30,2026

Early results from a trial of active surveillance for low-risk ductal carcinoma in situ are 'reassuring'

by European Organisation for Research and Treatment of CancerCredit: Unsplash/CC0 Public DomainResearchers leading a trial of active surveillance for ductal carcinoma in situ (DCIS) have described ear

Updated on:May 30,2026

AI model can predict chemotherapy benefit in breast cancer

byTechnion - Israel Institute of TechnologyStudy cohorts, deep learning system architecture, and performance evaluation on TAILORx-Test. Credit:The Lancet Oncology(2026). DOI: 10.1016/s1470-2045(25)00

Updated on: May 29,2026

AI model can predict chemotherapy benefit in breast cancer

byTechnion - Israel Institute of TechnologyStudy cohorts, deep learning system architecture, and performance evaluation on TAILORx-Test. Credit:The Lancet Oncology(2026). DOI: 10.1016/s1470-2045(25)00

Updated on:May 29,2026

AI learns to make sense of childhood cancer survivors' health care needs

bySt. Jude Children's Research HospitalCredit: SHVETS production from PexelsArtificial intelligence (AI) could help physicians determine if survivors of childhood cancer need extra support—and the

Updated on: May 28,2026

AI learns to make sense of childhood cancer survivors' health care needs

bySt. Jude Children's Research HospitalCredit: SHVETS production from PexelsArtificial intelligence (AI) could help physicians determine if survivors of childhood cancer need extra support—and the

Updated on:May 28,2026

Why some cancer therapies don't work for all patients: A tumor backup survival pathway

by Anne Trafton,Massachusetts Institute of TechnologyMany of the targeted tumors turn on a backup survival pathway that helps them keep growing when tyrosine kinase—pictured here as strands—is turned

Updated on: May 26,2026

Why some cancer therapies don't work for all patients: A tumor backup survival pathway

by Anne Trafton,Massachusetts Institute of TechnologyMany of the targeted tumors turn on a backup survival pathway that helps them keep growing when tyrosine kinase—pictured here as strands—is turned

Updated on:May 26,2026

PSMA therapy delays hormone therapy in prostate cancer, clinical trial finds

byRadboud UniversityNuclear medicine physician James Nagarajah from Radboudumc in the clinics. Credit: RadboudumcWhere previous research showed that PSMA therapy for prostate cancer can prolong the li

Updated on: May 25,2026

PSMA therapy delays hormone therapy in prostate cancer, clinical trial finds

byRadboud UniversityNuclear medicine physician James Nagarajah from Radboudumc in the clinics. Credit: RadboudumcWhere previous research showed that PSMA therapy for prostate cancer can prolong the li

Updated on:May 25,2026

Genetic variants involved in rapid immune response linked to earlier breast cancer onset in BRCA1 carriers

byBritish Medical JournalCredit: CC0 Public DomainDamaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer onset in carriers o

Updated on: May 24,2026

Genetic variants involved in rapid immune response linked to earlier breast cancer onset in BRCA1 carriers

byBritish Medical JournalCredit: CC0 Public DomainDamaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer onset in carriers o

Updated on:May 24,2026

A new immunotherapy target? How SRC-3 in Tregs may reshape solid-tumor treatment

by Ana María Rodríguez,Baylor College of MedicineThe loss of SRC-3 in Treg leads to immune suppression of glioblastoma in mice: (A) Experimental design for the orthotopic injection of glioblastoma cel

Updated on: May 23,2026

A new immunotherapy target? How SRC-3 in Tregs may reshape solid-tumor treatment

by Ana María Rodríguez,Baylor College of MedicineThe loss of SRC-3 in Treg leads to immune suppression of glioblastoma in mice: (A) Experimental design for the orthotopic injection of glioblastoma cel

Updated on:May 23,2026

An avatar to study pediatric brain cancer may soon be a reality

byUniversity of TrentoA summary of pPDT and pPDXT generation, amplification and biobanking and their use in drug screening and other applications. Credit:Nature Protocols(2026). DOI: 10.1038/s41596-02

Updated on: May 22,2026

An avatar to study pediatric brain cancer may soon be a reality

byUniversity of TrentoA summary of pPDT and pPDXT generation, amplification and biobanking and their use in drug screening and other applications. Credit:Nature Protocols(2026). DOI: 10.1038/s41596-02

Updated on:May 22,2026

uPAR-targeted CAR T cells shrank solid tumors and cleared metastases in mice

byMemorial Sloan Kettering Cancer CenterCredit:Cell(2026). DOI: 10.1016/j.cell.2026.03.002Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers li

Updated on: May 20,2026

uPAR-targeted CAR T cells shrank solid tumors and cleared metastases in mice

byMemorial Sloan Kettering Cancer CenterCredit:Cell(2026). DOI: 10.1016/j.cell.2026.03.002Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers li

Updated on:May 20,2026

TYK2 protein suppresses breast cancer metastasis by sensing extracellular stiffness, research finds

by Miles Martin,University of California - San DiegoIn healthy tissues, seen in the top two panels here, TYK2 (green) is found on the cell membrane and colocalizes with E-cadherin (red), a protein tha

Updated on: May 19,2026

TYK2 protein suppresses breast cancer metastasis by sensing extracellular stiffness, research finds

by Miles Martin,University of California - San DiegoIn healthy tissues, seen in the top two panels here, TYK2 (green) is found on the cell membrane and colocalizes with E-cadherin (red), a protein tha

Updated on:May 19,2026

After allogeneic transplant, VIC-1911 regimen shows low severe GVHD and no relapse

byRoswell Park Comprehensive Cancer CenterCredit: Unsplash/CC0 Public DomainResults of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a low

Updated on: May 19,2026

After allogeneic transplant, VIC-1911 regimen shows low severe GVHD and no relapse

byRoswell Park Comprehensive Cancer CenterCredit: Unsplash/CC0 Public DomainResults of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a low

Updated on:May 19,2026

New analytical method reveals how drug combinations act in leukemia

byTampere UniversityCoPISA workflow and possible states for target discovery in combinatorial therapy. Credit:Nature Communications(2026). DOI: 10.1038/s41467-026-70394-3Acute myeloid leukemia (AML) r

Updated on: May 15,2026

New analytical method reveals how drug combinations act in leukemia

byTampere UniversityCoPISA workflow and possible states for target discovery in combinatorial therapy. Credit:Nature Communications(2026). DOI: 10.1038/s41467-026-70394-3Acute myeloid leukemia (AML) r

Updated on:May 15,2026